8,720 results match your criteria IgA Nephropathy


Clinical importance of the updated Oxford classification in allograft IgA nephropathy.

Am J Transplant 2019 Apr 24. Epub 2019 Apr 24.

Kidney Research Institute, Seoul National University College of Medicine, Seoul, Korea.

With the recent update to the Oxford classification for allograft IgA nephropathy (IgAN), additional investigations on the clinical significance of the updated components are warranted. We performed a retrospective cohort study at two tertiary hospitals. Kidney transplant recipients diagnosed with allograft IgAN were included in the study after additional review by specialized pathologists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15400DOI Listing

Postinfectious Acute Glomerulonephritis in Renal Transplantation: An Emergent Aetiology of Renal Allograft Loss.

Case Rep Transplant 2019 18;2019:7438254. Epub 2019 Mar 18.

Department of Nephrology and Renal Transplantation, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Despite the high incidence of posttransplant infections, postinfectious acute glomerulonephritis (PIAGN) in renal allograft is a rare entity, without effective treatment and a bad prognosis. We describe two cases of PIAGN: the first one was developed 2 years after kidney transplantation, secondary to bacteremia with presence of extracapillary proliferation in biopsy. The patient was treated with methylprednisolone and plasma exchanges without response, remaining dialysis dependent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7438254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442439PMC

Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy.

Transplant Proc 2019 Apr 19. Epub 2019 Apr 19.

Department of Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.

Objective: The objective of this study was to analyze the impact of induction immunosuppression on the incidence of recurrent IgA nephropathy (IgAN).

Methods: We conducted recurrence-free survival analysis of recipients of a first kidney transplant for IgAN who received a graft between 1995 and 2015. Kaplan-Meier and Cox regression analyses were used to sort the significant risk factors for recurrence. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00411345183143
Publisher Site
http://dx.doi.org/10.1016/j.transproceed.2019.01.115DOI Listing
April 2019
2 Reads

Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?

Authors:
Jürgen Floege

Am J Kidney Dis 2019 Apr 17. Epub 2019 Apr 17.

Division of Nephrology, Medizinische Klinik II, RWTH University Hospital Aachen, Aachen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2019.02.022DOI Listing

[Adult IgA vasculitis (Henoch-Schönlein purpura)].

Nephrol Ther 2019 Apr;15 Suppl 1:S13-S20

Service de néphrologie et de transplantation, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm U1149, CRI, faculté de médecine Xavier-Bichat, 16, rue Henri-Huchard, 75018 Paris, France. Electronic address:

IgA vasculitis is a systemic vasculitis affecting small vessels. IgA vasculitis usually affect children whereas it is rare in adults (150 to 200 for 1) in which the disease is often more serious with more frequent and severe nephritis. Prevalence of adult IgA vasculitis is unknown and its annual incidence is 1 in 1 million. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17697255193000
Publisher Site
http://dx.doi.org/10.1016/j.nephro.2019.02.001DOI Listing
April 2019
2 Reads

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

JAMA Intern Med 2019 Apr 13. Epub 2019 Apr 13.

Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.

Importance: Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression. This limits patient-specific risk stratification and treatment decisions, clinical trial recruitment, and biomarker validation.

Objective: To derive and externally validate a prediction model for disease progression in IgAN that can be applied at the time of kidney biopsy in multiple ethnic groups worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2019.0600DOI Listing
April 2019
4 Reads

IgA Nephropathy Flare-Up Mimicking Staphylococcus Post-Infection Glomerulonephritis in Patient with Staphylococcus Aureus Infection Treated with Cefazolin: A Case Report and Brief Review of the Literature.

Am J Case Rep 2019 Apr 12;20:508-510. Epub 2019 Apr 12.

Department of Pharmacy Services, Piedmont Columbus Regional Healthcare System, Columbus, GA, USA.

BACKGROUND Glomerulonephritis (GN) associated with post staphylococcus infection (PSIGN) and high serum immunoglobulin A (IgA) has been reported recently. Patients with GN after infection with underlying IgA nephropathy create a challenge to determine the etiology of GN. Therefore, treatment should be accordingly, with steroids used if the IgA nephropathy flare-up is determined to be the etiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.914935DOI Listing
April 2019
5 Reads

Is IgA Nephropathy Different in Different Ethnic Populations?

Nephrology (Carlton) 2019 Apr 11. Epub 2019 Apr 11.

Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.

IgA nephropathy (IgAN) is one of the commonest global patterns of primary glomerulonephritis and remains a leading cause of chronic kidney disease and end stage renal disease. The sole diagnostic criterion of IgAN remains the presence of dominant mesangial IgA deposits on kidney biopsy. Beyond this defining feature, there is significant heterogeneity in the epidemiology, clinical presentation, renal progression and long term outcomes of IgAN in different ethnic populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nep.13592DOI Listing
April 2019
1 Read

Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy.

Clin Kidney J 2019 Apr 3;12(2):232-238. Epub 2018 Aug 3.

Department of Biomedicine, University of Basel, Basel, Switzerland.

Background: Galactose-deficient immunoglobulin A1 (Gd-IgA1) is known to play a key role in the pathogenesis of IgA nephropathy (IgAN). We aimed to evaluate whether serum Gd-IgA1 is associated with activation of mesangial cells in individual patients and how this affects the clinical and histologic parameters.

Methods: Serum samples and clinical and histologic data were collected in the University Hospital Basel and Hammersmith Hospital, London. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ckj/sfy068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452211PMC
April 2019
1 Read

Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.

J Am Soc Nephrol 2019 Apr 10. Epub 2019 Apr 10.

Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.

The clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis. Although some studies have suggested that mortality appears to be increased in IgAN, such studies lacked matched controls and did not report absolute risk.

Methods: We conducted a population-based cohort study in Sweden, involving patients with biopsy-verified IgAN diagnosed in 1974-2011; main outcome measures were death and ESRD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018101017DOI Listing
April 2019
4 Reads

Clinical and histological features and therapeutic strategies for IgA nephropathy.

Clin Exp Nephrol 2019 Apr 9. Epub 2019 Apr 9.

Department of Nephrology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Chronic glomerulonephritis is the second most common reason, after diabetic nephropathy, for initiation of dialysis in Japan and IgA nephropathy (IgAN) is the most prevalent form of chronic glomerulonephritis. In the half century since IgAN was initially reported, our understanding of the long-term prognosis, clinical and histological features, pathogenesis of onset and progression, risk factors for progression, and appropriate treatment under different clinical and histological conditions, has steadily increased. Strong experimental and clinical evidence, the Clinical Practice Guidelines for IgA Nephropathy in Japan, the Oxford Classification, and the Kidney Disease Improving Global Outcomes guidelines have all contributed to the appropriate treatment of IgAN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10157-019-01735-4DOI Listing
April 2019
3 Reads

A Rare Genetic Defect of Increased the Risk for Progression of IgA Nephropathy.

Front Immunol 2019 22;10:537. Epub 2019 Mar 22.

Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

The aim of this study was to investigate the association between lectin pathway-related genetic variations and progression in IgA nephropathy. Biopsy-proven IgAN patients with eGFR ≥15 ml/min/1.73 m at baseline and a minimum follow-up of 12-months were enrolled. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00537
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438956PMC
March 2019
6 Reads

Cast nephropathy associated with monoclonal immunoglobulin M-secreting mucosa-associated lymphoid tissue B-cell lymphoma
.

Clin Nephrol 2019 Apr 9. Epub 2019 Apr 9.

The kidney is among the various anatomical sites involved in mucosa-associated lymphoid tissue (MALT) lymphoma. A variety of renal pathological types, including membranous glomerulopathy, membranoproliferative glomerulonephritis, crescentic IgA nephropathy, minimal change disease, and cryoglobulinemic glomerulopathy, have been reported in MALT lymphoma patients. However, cast nephropathy is extremely rare in MALT lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CN109682DOI Listing
April 2019
4 Reads

Diagnostic role of renal biopsy in PLAR1-antibody-positive patients with nephrotic syndrome.

Mod Pathol 2019 Apr 8. Epub 2019 Apr 8.

III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Renal biopsy is the gold standard for diagnosis of membranous nephropathy. Circulating PLAR1 antibody found in 75% of patients with membranous nephropathy is very specific for the diagnosis of this disease. Therefore, the question arises whether PLAR1-antibody-positive patients still need a diagnostic renal biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0267-zDOI Listing
April 2019
1 Read

Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome.

Immun Inflamm Dis 2019 Apr 7. Epub 2019 Apr 7.

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Introduction: Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. It is well known that upper respiratory tract infections, particularly acute tonsillitis, often worsen IgAN. Recent many clinical studies clearly show that tonsillectomy with steroid pulse therapy is the effective treatments for IgAN patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/iid3.248DOI Listing
April 2019
5 Reads

Rapidly Progressive Glomerulonephritis Secondary to IgA Nephropathy in a Patient with Systemic Lupus Erythematosus.

Case Rep Nephrol 2019 5;2019:8354823. Epub 2019 Mar 5.

Department of Internal Medicine, Division of Nephrology, Houston, TX, USA.

Lupus nephritis is a common manifestation of systemic lupus erythematosus (SLE). IgA nephropathy is a common type of primary glomerulonephritis. Renal manifestations in SLE patients are often due to lupus nephritis; however, renal diseases unrelated to lupus nephritis are rarely reported. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crin/2019/8354823/
Publisher Site
http://dx.doi.org/10.1155/2019/8354823DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425374PMC
March 2019
4 Reads

Urine exosomal ceruloplasmin: a potential early biomarker of underlying kidney disease.

Clin Exp Nephrol 2019 Apr 6. Epub 2019 Apr 6.

Division of Nephrology, John H. Stroger, Jr. Hospital of Cook County, 1950 West Polk Street, Suites 5-56, Professional Building, Chicago, IL, 60612, USA.

Background: Previously we found that kidney tissue and urinary exosomes from patients of diabetic kidney disease showed high levels of ceruloplasmin (CP). Because CP is an acute-phase protein of kidney origin, it could be an early marker of many other kidney diseases. To investigate this hypothesis, we first measured urine exosomal and kidney expression of CP in non-diabetic chronic kidney disease (CKD) patients (membranous nephropathy, focal segmental glomerulosclerosis, lupus nephritis and IgA nephropathy) followed by a longitudinal study in rat passive Heymann nephritis (PHN), a model of human membranous nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10157-019-01734-5DOI Listing
April 2019
2 Reads

Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.

Pediatr Nephrol 2019 Apr 6. Epub 2019 Apr 6.

Department of Pediatric Nephrology and Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Stenbäckinkatu 9, 00290, Helsinki, Finland.

Background: Optimal treatment of Henoch-Schönlein purpura nephritis (HSN) remains unclear. We evaluated outcome of pediatric HSN patients treated initially with either methylprednisolone (MP) or cyclosporine A (CyA) in Finland between 1996 and 2011.

Methods: Outcome of 62 HSN patients was evaluated by screening urine and blood samples (n = 51) or by collecting clinical parameters from medical charts until last follow-up visit (n = 11). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-019-04238-2DOI Listing
April 2019
3 Reads

Urinary angiostatin: a novel biomarker of kidney disease associated with disease severity and progression.

BMC Nephrol 2019 Apr 3;20(1):118. Epub 2019 Apr 3.

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, 100853, China.

Background: This study aimed to evaluate the value of urinary angiostatin levels for assessing disease severity and progression of IgA nephropathy (IgAN).

Methods: Urinary angiostatin was identified as one of the distinct proteins in samples of patients with IgAN analyzed by Raybiotech protein array, and further confirmed by enzyme-linked immunosorbent assay (ELISA).

Results: Urinary angiostatin levels were significantly higher in IgAN patients than that in healthy controls (HC) subjects and lower than in disease controls (DC) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-019-1305-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446319PMC
April 2019
2 Reads
1.520 Impact Factor

A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab.

CEN Case Rep 2019 Apr 3. Epub 2019 Apr 3.

Division of Nephrology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

A 60-year-old man was diagnosed with psoriasis 4 years ago. Treatment with adalimumab (a monoclonal anti-TNF-α antibody) became ineffective 1 year ago, and proteinuria and urinary occult blood were detected. Treatment with topical medicine, ultraviolet therapy, and etretinate resulted in remission of psoriasis, and proteinuria and hematuria also improved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13730-019-00393-5DOI Listing
April 2019
4 Reads

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Front Immunol 2019 19;10:504. Epub 2019 Mar 19.

Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, United States.

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is necessary for diagnosis, with routine immunofluorescence microscopy revealing dominant or co-dominant IgA immunodeposits usually with complement C3 and sometimes IgG and/or IgM. IgA nephropathy reduces life expectancy by more than 10 years and leads to kidney failure in 20-40% of patients within 20 years of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433978PMC
March 2019
5 Reads

Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis.

Mod Pathol 2019 Apr 1. Epub 2019 Apr 1.

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Complement factor C4d was recently observed in renal biopsies from patients who had IgA nephropathy and a poor prognosis. We previously reported that C4d is a common denominator in microangiopathies. In this retrospective cohort study, we investigated whether C4d is a marker of microangiopathy in both IgA nephropathy and IgA vasculitis with nephritis, and whether patients with C4d and microangiopathy have poor renal outcome. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-019-0259-z
Publisher Site
http://dx.doi.org/10.1038/s41379-019-0259-zDOI Listing
April 2019
10 Reads

Adalimumab-induced IgA nephropathy.

BMJ Case Rep 2019 Mar 31;12(3). Epub 2019 Mar 31.

Renal, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.

Immunoglobulin A nephropathy (IgAN) is the most commonly diagnosed glomerulonephritis worldwide. It is usually idiopathic and may be associated with many other diseases. Recently, biological agents including tumour necrosis factor alpha (TNFα) inhibitors have been identified as a potential cause for IgAN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226442DOI Listing
March 2019
2 Reads

3'UTR variants of TNS3, PHLDB1, NTN4, and GNG2 genes are associated with IgA nephropathy risk in Chinese Han population.

Int Immunopharmacol 2019 Mar 28;71:295-300. Epub 2019 Mar 28.

Department of Nephrology, Hainan General Hospital, Hainan, Haikou, Hainan 570311, China. Electronic address:

Background: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and is characterized by mesangial cell proliferation and agglomeration of the mesangial matrix.

Methods: In this study, we aimed to explore the role of TNS3, PHLDB1, NTN4, and GNG2 3'untranslated region (3'UTR) polymorphisms with the risk of IgAN in a Chinese Han cohort. A logistic recession model was used to calculate the effects of candidate single nucleotide polymorphism (SNP) on IgAN risk after adjusting age and gender difference. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2019.03.041DOI Listing
March 2019
2 Reads

Clinical impact of endocapillary proliferation with modified cutoff points in IgA nephropathy patients.

PLoS One 2019 29;14(3):e0214414. Epub 2019 Mar 29.

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Predictive values of mesangial proliferation (M), endocapillary proliferation (E), segmental glomerulosclerosis (S), and crescents (C) among 19 validation studies of the Oxford Classification of IgA nephropathy (IgAN) were discrepant, especially in Asian patients. These validation studies indicate that cutoffs of MESC score in the Oxford Classification may not be generalizable. Thus, we aimed to improve the clinical value of MESC scores by modifying the cutoff points. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214414PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440693PMC
March 2019
1 Read

[Renal prognosis of IgA vasculitis nephritis in adult patients: a monocentric study of 25 cases].

Pan Afr Med J 2018 4;31. Epub 2018 Sep 4.

Service de Médecine Interne A, Hopital Charles Nicolle, Tunis, Tunisie.

IgA vasculitis nephritis affects the prognosis of this disease in adult patients. This study aimed to examine the clinical characteristics of this renal involvement in adults and to identify factors influencing renal prognosis. We conducted a retrospective monocentric study of patients with histologically confirmed IgA vasculitis nephritis (rheumatoid purpura) (EULAR classification criteria) with renal involvement classified according to Pillebout classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.31.9.10594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431421PMC
April 2019
1 Read

Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.

Am J Kidney Dis 2019 Mar 25. Epub 2019 Mar 25.

Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China.

Rationale & Objective: Despite optimization of renin-angiotensin-aldosterone system (RAAS) inhibition, patients with immunoglobulin A nephropathy (IgAN) and persistent proteinuria remain at risk for kidney failure. We evaluated the efficacy and safety of hydroxychloroquine (HCQ), an immunomodulator, when added to the treatment regimen of patients with IgAN.

Study Design: Double-blind, randomized, placebo-controlled, phase 2 clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2019.01.026DOI Listing
March 2019
1 Read

La ponction biopsie rénale: indications, complications et résultats.

Pan Afr Med J 2018 20;31:44. Epub 2018 Sep 20.

Centre Hospitalier Universitaire Mohammed VI, Oujda, Maroc.

Renal needle biopsy (RNB) is the gold standard in the diagnosis of kidney diseases. It is an invasive technique causing several complications, in particular hemorrhagic events. This study aims to evaluate our RNB practice, to update the current understanding of the technique for percutaneous renal biopsy, to assess complications and to determine the prevalence of kidney diseases diagnosed in our region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.31.44.15604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430949PMC
April 2019
1 Read

A Patient with MPO-ANCA-positive IgA Nephropathy Diagnosed with the Clinical Onset of Macrohematuria.

Intern Med 2019 Mar 28. Epub 2019 Mar 28.

Department of Internal Medicine, Teikyo University School of Medicine, Japan.

A 21-year-old woman presented with renal dysfunction during macrohematuria. A kidney biopsy revealed IgA nephropathy with asmall percentage of crescent formation and macrohematuria-associated tubular injury. Macrohematuria-associated acute kidney injury could explain her renal dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2475-18DOI Listing
March 2019
1 Read

[Clinicopathologic features and prognosis of patients with IgA nephropathy superimposed on transplant glomerulopathy].

Zhonghua Yi Xue Za Zhi 2019 Mar;99(12):889-894

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China.

To observe the clinicopathologic features and prognostic of patients with IgA nephropathy (IgAN) superimposed on transplant glomerulopathy (TG+ IgAN). Electronic medical records of Jinling Hospital were searched for TG+ IgAN patients that was diagnosed during January 2004 to December 2016. Clinicopathologic features and prognoses information were retrieved and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2019.12.003DOI Listing
March 2019
1 Read

Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.

Am J Nephrol 2019 27;49(4):307-316. Epub 2019 Mar 27.

Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, China,

Background: Aberrant O-glycosylation IgA1 production is a major factor in the pathogenesis of IgA nephropathy, but the underlying mechanism is still unclear. IgA1 glycosylation modification is in Golgi, and downregulation of the Golgi peripheral membrane protein Golgi matrix protein 130 (GM130) could lead to glycosylation deficiency. In this study, we aimed to explore the role of GM130 in glycosylate deficiency IgA1 (Gd-IgA1) production. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499110DOI Listing
March 2019
6 Reads

Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.

PLoS One 2019 27;14(3):e0214256. Epub 2019 Mar 27.

Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.

Background: IgA nephropathy(IgAN) is a common glomerular disease with a higher risk of progression to end stage renal disease (ESRD) in certain ethnic populations. Since galactose deficient IgA1(Gd-IgA1) is a critical molecule in its pathogenesis, it has generated interest as a biomarker for this disease.

Methods: We measured serum Gd-IgA1 levels using a non- lectin based enzyme linked immunoassay(ELISA) in 136 immunosuppression naïve patients with primary IgAN and 110 controls(60-non IgA glomerular diseases, 50-healthy volunteers). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214256PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436754PMC
March 2019
1 Read
3.234 Impact Factor

Pyomyositis in a Patient with IgA Nephropathy and Kidney Transplant.

Case Rep Transplant 2019 28;2019:7305683. Epub 2019 Jan 28.

Nephrology and Renal Transplantation Department, Hospital Clinic of Barcelona, Experimental Laboratory in Nephrology and Kidney Transplant (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain.

Infections are among the most common complications transplant physicians face when dealing with solid organ transplant recipients. We present a case of pyomyositis caused by in a patient with IgA nephropathy and a kidney transplant, under treatment with mTOR inhibitors and prednisone. This entity is a rare intramuscular infection, given the resistance of healthy muscle to colonization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7305683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398059PMC
January 2019
1 Read

[Clinical effect of tacrolimus combined with glucocorticoid in the treatment of IgA nephropathy in children].

Zhongguo Dang Dai Er Ke Za Zhi 2019 Mar;21(3):265-270

Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Clinical Center of Pediatric Nephrology of Henan Province, Zhengzhou 450052, China.

Objective: To study the clinical effect and safety of tacrolimus (TAC) combined with glucocorticoid (GC) versus mycophenolate mofetil (MMF) combined with GC in the treatment of primary IgA nephropathy (IgAN) in children.

Methods: A retrospective analysis was performed for the clinical data of children with primary IgAN confirmed by renal pathology between January 2012 and December 2017. These children were divided into TAC group and MMF group according to the treatment regimen. Read More

View Article

Download full-text PDF

Source
March 2019
7 Reads

Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch.

Hum Immunol 2019 Mar 20. Epub 2019 Mar 20.

Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2019.03.015DOI Listing
March 2019
3 Reads

IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description.

Kidney Int 2019 Apr;95(4):750-756

Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.

On September 27-29, 2018, the International Symposium on IgA Nephropathy, organized by the International IgA Nephropathy Network, was held in Buenos Aires, Argentina, celebrating the 50th anniversary of the first description of IgA nephropathy by Berger and Hinglais in 1968. The meeting was attended by over 200 scientists and clinicians from 26 different countries across the globe. We report some key insights drawn from the meeting-including the molecular pathogenesis, genetics, pathology, and therapeutics of IgA nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.007DOI Listing
April 2019
1 Read

Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis.

J Am Acad Dermatol 2019 Mar 19. Epub 2019 Mar 19.

Department of Translational Dermatoinfectiology, University of Münster, Münster, Germany; Department of Dermatology and Venereology, University Hospital of Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. Electronic address:

Background: IgA-vasculitis (IgAV) encompasses a systemic form involving kidneys, gut, skin or joints, and a skin-limited form. One characteristic feature of systemic IgAV is deposition of galactose-deficient IgA1 (GD-IgA1) in kidneys (as in IgA-nephropathy). The relevance of GD-IgA1 for cutaneous vasculitis is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.03.029DOI Listing
March 2019
1 Read

Is it possible to predict the evolution of IgAN? Validation of the IgA nephropathy progression calculator and its relationship with MEST-C score in our population.

Nefrologia 2019 Mar 19. Epub 2019 Mar 19.

Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Cantabria, España.

Introduction: IgA nephropathy (IgAN) is the most common and heterogeneous glomerular nephropathy. Several strategies have been used to determine the risk of progression to ESRD. We evaluate the prognostic significance and correlate the IgAN progression calculator (IgANPC) and the Oxford/MEST-C score in our population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.10.015DOI Listing
March 2019
1 Read

Health-related quality of life in glomerular disease.

Kidney Int 2019 May 27;95(5):1209-1224. Epub 2019 Feb 27.

Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.

There is scant literature describing the effect of glomerular disease on health-related quality of life (HRQOL). The Cure Glomerulonephropathy study (CureGN) is an international longitudinal cohort study of children and adults with four primary glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy). HRQOL is systematically assessed using items from the Patient-Reported Outcomes Measurement Informative System (PROMIS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2018.12.018DOI Listing
May 2019
3 Reads

p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients.

PLoS One 2019 21;14(3):e0213981. Epub 2019 Mar 21.

Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea.

Activation of p38 mitogen-activated protein kinase (MAPK) is associated with tissue fibrosis, and inhibition of p38 MAPK can attenuate the progression of fibrosis. We aimed to investigate whether p38 MAPK activity in kidney tissue confirmed by immunohistochemical staining is associated with renal tubulointerstitial fibrosis in chronic kidney disease patients with IgA nephropathy. We collected kidney biopsy specimens from 341 IgA nephropathy patients and 15 control patients to identify the clinical and histopathological factors associated with kidney tubulointerstitial fibrosis and to find an association between kidney phosphorylated p38 immunoactivity and pathological grading. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213981PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428396PMC
March 2019
1 Read

[Immunoglobulin A nephropathy].

Internist (Berl) 2019 Mar 20. Epub 2019 Mar 20.

Medizinische Klinik II (Klinik für Nieren- und Hochdruckkrankheiten, rheumatologische und immunologische Erkrankungen), Universitätsklinikum, RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.

Immunoglobulin A nephropathy (IgAN) is the most prevalent primary form of glomerulopathy in the western world. The pathogenetic relevance of autoimmune mechanisms, genetics and environmental or nutritional factors is not fully established. The majority of IgAN patients present with mild symptoms; however, the exact prognosis of the individual IgAN course is often difficult to predict. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0588-5DOI Listing
March 2019
4 Reads

Hyperuricemia and its related histopathological features on renal biopsy.

BMC Nephrol 2019 Mar 18;20(1):95. Epub 2019 Mar 18.

Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.

Background: Hyperuricemia (HUA) is very common in chronic kidney disease (CKD). HUA is associated with an increased risk of cardiovascular events and accelerates the progression of CKD. Our study aimed to explore the relationship between baseline serum uric acid levels and renal histopathological features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-019-1275-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423852PMC
March 2019
2 Reads
1.520 Impact Factor

Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response.

Ren Fail 2019 Nov;41(1):104-112

c Department of Traditional Chinese Medicine , Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital , Chengdu , PR China.

Immunoglobulin A nephropathy (IgAN) is characterized by mesangial IgA and IgG co-deposition. As the clinical course of IgAN is highly variable, a lot of patients will eventually develop to end-stage renal disease (ESRD) within years. Hirudin, a potent and specific thrombin inhibitor, has been reported to treat IgAN with hematuria, but the mechanism is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0886022X.2019.1583113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427573PMC
November 2019
7 Reads

Uremic Pancolitis in an Adult Patient with Newly Diagnosed, Rapidly Progressive Crescentic Immunoglobulin A Nephropathy.

Cureus 2019 Jan 4;11(1):e3826. Epub 2019 Jan 4.

Nephrology, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA.

Uremic gastroenteropathy is a well-accepted but less often described sequelae of an underlying renal disease. With the advent of modern dialysis treatments, rarer manifestations, such as pancolitis, may go overlooked in the evaluation, pursuing more common diagnoses. The underlying pathophysiology of uremic gastroenteropathy is not completely understood; however, several underlying mechanisms have been identified to play a role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402858PMC
January 2019

A non-invasive diagnostic model of immunoglobulin A nephropathy and serological markers for evaluating disease severity.

Chin Med J (Engl) 2019 Mar;132(6):647-652

Department of Nephrology, Chinese People's Liberation Army General Hospital, Chinese People's Liberation Army Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing 100853, China.

Background: Immunoglobulin A nephropathy (IgAN) is the most common pathological type of glomerular disease. Kidney biopsy, the gold standard for IgAN diagnosis, has not been routinely applied in hospitals worldwide due to its invasion nature. Thus, we aim to establish a non-invasive diagnostic model and determine markers to evaluate disease severity by analyzing the serological parameters and pathological stages of patients with IgAN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416104PMC
March 2019
1 Read

Immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via regulating the differentiation of CD4+ T cell subsets in rats.

Int Immunopharmacol 2019 May 7;70:313-323. Epub 2019 Mar 7.

Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. Electronic address:

Immunoglobulin A nephropathy (IgAN) is an autoimmune kidney disease with complex pathogenesis leading to end-stage renal damage. The crucial pathological characteristic in IgAN is IgA immune complexes deposition accompany with mesangial cell proliferation and mesangial matrix expansion. Artemisinin (ART) is isolated from traditional Chinese medicine Artemisia annua L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2019.02.056DOI Listing
May 2019
2 Reads
2.472 Impact Factor

Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis.

Int Urol Nephrol 2019 Mar 6. Epub 2019 Mar 6.

Department of Nephrology, Institute of Nephrology and Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China.

Background: The efficacy and safety of glucocorticoids for the treatment of patients with IgA nephropathy (IgAN) remains controversial. The aim of the study is to perform a metaanalysis of randomized controlled trials to evaluate the efficacy and safety of glucocorticoids for patients with IgAN.

Methods: We searched PubMed, EMBASE and the Cochrane Library and article reference lists of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing glucocorticoids with other non-immunosuppressive agents in patients with IgAN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-019-02094-5DOI Listing
March 2019
1 Read

Variation in Complement Factor H Affects Complement Activation in Immunoglobulin A Vasculitis with Nephritis.

Nephrology (Carlton) 2019 Mar 6. Epub 2019 Mar 6.

Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.

Background: Immunoglobulin A vasculitis with Nephritis (IgAVN) and IgA nephropathy (IgAN) are widely considered as related diseases. Considerable evidences support the notion of involvement of complement activation in both IgAVN and IgAN. Our previous studies identified a genetic variant in complement factor H (CFH), rs6677604, as an IgAN-susceptible variant by genome-wide association study (GWAS), and further confirmed its linkage to CFHR3-1∆ and proved its influence on complement activation and thereby on IgAN susceptibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nep.13580DOI Listing
March 2019
1 Read